The Utility of Health and Wealth for HIV Patients on Antiretroviral Therapy in Kenya
Asian Journal of Probability and Statistics,
Aims/ Objectives: To determine the appropriate utility function that models the trade o between health and wealth for HIV/AIDS patients on Antiretroviral Therapy in Kenya.
Study Design: Retrospective study.
Place and Duration of Study: Jomo Kenyatta University of Agriculture and Technology, between January 2019-April 2022.
Methodology: The study involved a retrospective study of 2800 patients on Antiretroviral Therapy in Kenya from the period of 2005-2017. All the records are in terms of random patient id and in no way is the privacy and anonymity of patients is compromised. The inclusion criteria is patients who had complete information on the covariates used in the model over the follow up period. The logarithmic utility function, the negative exponential utility function and the power utility function are compared using the Akaike Information Criterion to determine which one best fits the empirical data to model the health and wealth trade off of patients on Antiretroviral Therapy in Kenya.
Results: Women constituted 66% of the sample. Only patients over the age of 18 years were included in the study. The mean age was 40.3. The health related quality of life values were calculated for each patient on Antiretroviral Therapy using the proxy utility function approach. The costs associated with receiving Antiretroviral Therapy treatment were obtained from simulating from a gamma distribution with ranges from existing published literature. The logarithmic utility function had the least AKaike Information Criterion.
Conclusion: The marginal utility of health increases with wealth for People living with HIV and the logarithmic utility function is suitable for modelling the shape of preferences for the trade off between health and wealth for HIV patients on Antiretroviral Therapy.
How to Cite
Brazier J, Ratcliffe J, Saloman J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. OXFORD university press; 2017.
Muennig P, Bounthavong M. Cost-effectiveness analysis in health: a practical approach. John Wiley & Sons; 2016.
Peterson C, Skolits G. Value for money: A utilization-focused approach to extending the foundation and contribution of economic evaluation. Evaluation and Program Planning. 2020;80:101799.
Lara AM, Wakholi BN, Kasirye A, Munderi P, Watera C, Lalloo DG, Grosskurth
H. Utility assessment of hiv/aids-related health states in HIV-infected ugandans. Aids. 2008;22:S123–S130.
Nosyk B, Min JE, Zang X, Feaster DJ, Metsch L, Marshall BD, Montaner JS. Why maximizing quality-adjusted life years, rather than reducing hiv incidence, must remain our objective in addressing the hiv/aids epidemic. Journal of the International Association of Providers of AIDS Care (JIAPAC). 2019;18:2325958218821962.
Levy M, Nir AR. The utility of health and wealth. Journal of Health Economics. 2012;31(2):379–392.
Torrance GW. Utility approach to measuring health-related quality of life. Journal of Chronic Diseases. 1987;40(6):593–600.
Whitham HK, Hutchinson AB, Shrestha RK, Kuppermann M, Grund B, Shouse RL, Sansom SL. Health utility estimates and their application to hiv prevention in the united states: Implications for cost-effectiveness modeling and future research needs. MDM Policy and Practice. 2020;5(2):2381468320936219.
Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs. Journal of Health Economics. 1997;16:155–175.
Deo V, Grover G. A new approach to evaluate quality adjusted life years using proxy utility function-an application to hiv/aids data. Journal of Communicable Diseases. (E-ISSN: 2581- 351X & P-ISSN: 0019-5138), 2019;51(3):1–9.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015.
Viscusi WK, Evans WN. Utility functions that depend on health status: estimates and economic implications.American Economic Review. 1990;80: 353–374.
Markowitz HM, Reid DW, Tew BV. The value of a blank check. Journal of Portfolio Management. 1994;20(4):82.
Merton RC, Samuelson PA. Fallacy of the log-normal approximation to optimal portfolio decision-making over many periods. Journal of Financial Economics. 1974;1(1):67–94.
Sinn HW. Weber’s law and the biological evolution of risk preferences: The selective dominance of the logarithmic utility function, 2002 geneva risk lecture. The Geneva Papers on Risk and Insurance Theory. 2003;28(2):87–100.
Miyamoto JM. Quality-adjusted life years (qaly) utility models under expected utility and rank dependent utility assumptions. Journal of Mathematical Psychology. 1999;43(2):201–237.
Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 19. 1974;716–723.
Abstract View: 30 times
PDF Download: 13 times